NIOX Group Plc Stock

Equities

CIR

GB00BJVD3B28

Pharmaceuticals

Market Closed - London S.E. 11:35:19 2024-04-19 am EDT 5-day change 1st Jan Change
64.6 GBX 0.00% Intraday chart for NIOX Group Plc -1.37% -3.58%
Sales 2024 * 42.44M 52.5M Sales 2025 * 48.12M 59.52M Capitalization 274M 339M
Net income 2024 * 12M 14.84M Net income 2025 * 14M 17.32M EV / Sales 2024 * 5.8 x
Net cash position 2024 * 27.61M 34.15M Net cash position 2025 * 36.32M 44.93M EV / Sales 2025 * 4.94 x
P/E ratio 2024 *
23.9 x
P/E ratio 2025 *
20 x
Employees 92
Yield 2024 *
1.67%
Yield 2025 *
2.09%
Free-Float 45.78%
More Fundamentals * Assessed data
Dynamic Chart
1 week-1.37%
Current month+0.94%
3 months+9.49%
6 months-3.00%
Current year-3.58%
More quotes
1 week
63.20
Extreme 63.2
67.60
1 month
62.38
Extreme 62.375
68.00
Current year
57.20
Extreme 57.2
68.00
1 year
43.10
Extreme 43.1
75.00
3 years
27.50
Extreme 27.5
75.00
5 years
12.50
Extreme 12.5
75.00
10 years
12.50
Extreme 12.5
356.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 59 20-01-08
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 19-09-01
Members of the board TitleAgeSince
Chairman 71 19-12-04
Director of Finance/CFO 59 20-01-08
Director/Board Member 67 20-03-01
More insiders
Date Price Change Volume
24-04-19 64.6 0.00% 208,023
24-04-18 64.6 -0.62% 450,806
24-04-17 65 -0.61% 2,116,328
24-04-16 65.4 0.00% 62,514
24-04-15 65.4 -0.15% 648,956

Delayed Quote London S.E., April 19, 2024 at 11:35 am EDT

More quotes
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company's product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.646 GBP
Average target price
0.76 GBP
Spread / Average Target
+17.65%
Consensus

Annual profits - Rate of surprise